Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).

被引：0
作者：
Berghoff, A.
Bartsch, R.
Bago-Horvath, Z.
Dubsky, P. C.
Rudas, M.
Pluschnig, U.
Wiltschke, C.
Gnant, M.
Steger, G. G.
Zielinski, C.
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Div Clin Oncol, Dept Med 1, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Med Univ Vienna, Dept Surg, Vienna, Austria
[5] Med Univ Vienna, Vienna, Austria
[6] Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Vienna, Austria
[7] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
572
引用
收藏
页数：1
相关论文
共 50 条
[31]   Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis [J].
DeBusk, Kendra ;
Abeysinghe, Shaun ;
Vickers, Adrian ;
Nangia, Anubhav ;
Bell, Judith ;
Ike, Chiemeka ;
Forero-Torres, Andres ;
Blahna, Matthew T. .
FUTURE ONCOLOGY, 2021, 17 (33) :4635-4647
[32]   Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy [J].
Badve, S. S. ;
Li, L. ;
Thorat, M. A. ;
Gagnon, R. C. ;
Ellis, C. E. ;
O'Shaughnessy, J. ;
Blackwell, K. L. ;
Baselga, J. ;
Sledge, G. W. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[33]   Efficacy of HER2-targeted therapy for patients with HER2-positive breast cancer according to hormone receptor status. [J].
Murata, Takeshi ;
Takahashi, Maiko ;
Hayashida, Tetsu ;
Jinno, Hiromitsu ;
Kitagawa, Yuko .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
[34]   Exploring Targeted Therapy for HER2-Positive Metastatic Breast Cancer [J].
Terrie, Yvette C. .
US PHARMACIST, 2022, 47 (10) :34-39
[35]   Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. [J].
Michiels, Stefan ;
Pugliano, Lina ;
Grun, DElphins ;
Barinoff, Jana ;
Cameron, David A. ;
Cobleigh, Melody A. ;
Di Leo, Angelo ;
Johnston, Stephen R. D. ;
Gasparini, Giampietro ;
Kaufman, Bella ;
Marty, Michel E. ;
Nekljudova, Valentina ;
Paluch-Shimon, Shani ;
Penault-Llorca, Frederique ;
Slamon, Dennis J. ;
Vogel, Charles L. ;
Von Minckwitz, Gunter ;
Buyse, Marc E. ;
Piccart-Gebhart, Martine J. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[36]   MNX1 promotes tumor sensitivity to HER2-targeted therapy in HER2-positive breast cancer [J].
Chi, Wei-Ru ;
Xiu, Bingqiu ;
Xiong, Min ;
Li, Pei ;
Zhang, Qi ;
Li, Lun ;
Hou, Jianjing ;
Zhou, Xujie ;
Sang, Yuting ;
Chen, Ming ;
Zhang, Liyi ;
Xue, Jingyan ;
Chi, Yayun ;
Wu, Jiong .
CANCER RESEARCH, 2023, 83 (05)
[37]   EFFICACY OF HER2-TARGETED ANTIBODY THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS [J].
Hulsbergen, Alexander ;
Broekman, Marike ;
Smith, Timothy ;
Aizer, Ayal A. ;
Iorgulescu, Bryan .
NEURO-ONCOLOGY, 2020, 22 :131-131
[38]   Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer [J].
Gupta, Anshul ;
Gogia, Ajay ;
Deo, S. V. S. ;
Sharma, D. N. ;
Mathur, Sandip ;
Sagiraju, Hari Krishna Raju .
CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 36
[39]   TRASTUZUMAB-BASED THERAPY AFTER DISEASE PROGRESSION FOLLOWING LAPATINIB AND CAPECITABINE IN HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC) [J].
Metro, G. ;
Fabi, A. ;
Foglietta, J. ;
Russillo, M. ;
Stocchi, L. ;
Crino, L. ;
Papaldo, P. ;
Sperduti, I. ;
Cognetti, F. ;
Gori, S. .
ANNALS OF ONCOLOGY, 2010, 21 :100-101
[40]   Recurrence risk prediction model in HER2-positive early breast cancer after HER2-targeted therapy [J].
Shang, Qingyao ;
Yu, Alison M. ;
Zou, Haotian ;
He, Youwen ;
Wang, Xin ;
Luo, Sheng .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL) :1035-1035
12345